title: [Effects of geniposide on treating experimental chronic prostatitis rats].
abstract: OBJECTIVE
  To study the effect of geniposide on treating experimental CP rats.
  
  
  METHODS
  The animal model of CP was made with rats by injecting hemorrhoid injection. Rats in experiment group were randomly devided into model group, Qianliekang tablets group (2 g x kg(-1)) and geniposide high, middle, low dose groups (20, 10, 5 mg x kg(-1)). Subsequently, the state of all rats, prostate index, WBC and lecithine corpuscle, LDH5/LDH1, and prostatic histopathological changes were observed. Count of total cellular score (TCS) and quantitation of inflammatory cell, fibroblasts, glandular organ, calculation of glandular cavity area, and their changes of morphology were analyzed.
  
  
  RESULTS
  Compared with model group, the prostate index, WBC and LDHS/LDH1 of the rats in Qianliekang tablets group, high dose geniposide group and middle dose geniposide group were significantly decreased, while the quantities of lecithine corpuscle were remarkably increased (P < 0.01 or P < 0.05). Compared with model group, the number of inflammatory cells and fibroblasts in Qianliekang tablets group, high dose geniposide group were decreased, and the quantity of glandular organ and area of glandular cavity in these groups were increased (P < 0.05 or P < 0.01).
  
  
  CONCLUSIONS
  Geniposide of high and middle dose can reduce leucocytes infiltration, restrain the hyperplasia of fibrous tissue, and recover the secretion function of prostate. It show that geniposide is significantly potential to cure rats which are exposed to chronic prostatitis.
authors.affiliation: Experiment Center of Function, Medical College of Chinese People's Armed Police Force, Tianjin 300162, China.
authors.forename: Yuzhang
authors.initials: Y
authors.lastname: Jin
authors.forename: Ruibo
authors.initials: R
authors.lastname: He
authors.forename: Yihe
authors.initials: Y
authors.lastname: Wang
authors.forename: Wenli
authors.initials: W
authors.lastname: Xie
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D002908:Chronic Disease / Q000188:drug therapy; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D039823:Iridoids / Q000494:pharmacology* / Q000627:therapeutic use; D007527:Isoenzymes / Q000378:metabolism; D007770:L-Lactate Dehydrogenase / Q000378:metabolism; D000080864:Lactate Dehydrogenase 5; D007958:Leukocyte Count; D008297:Male; D011467:Prostate / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D011472:Prostatitis / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley
chemical_list: D039823:Iridoids; D007527:Isoenzymes; C007835:geniposide; D007770:L-Lactate Dehydrogenase; D000080864:Lactate Dehydrogenase 5; C409667:lactate dehydrogenase 1